bigbanktheory wrote: it's just a guess, and the reason being is that the big mj companies might not be hitting analysts expecatations, sure mj sales could start to pick up in the coming months, but in order to expand and grow revenues, they might start buying out good mj medical companies.  

this is all just a guess, why would a major mj company wait for a phase three when phase two could be very successful, and possibly a much higher stock price, anyways, I'm holding for a year, 

GL to all, do your own due diligence


If they want to expand and grow revenues... why would they buy Kaly? They wont see revs for 5 years minimum, and thats a best case scenario that they pass phase 2 and 3. PLus Kaly is the furthest thing from a good medical mj company. They are run like a lemonade stand. 

I agree a medically focused LP like TRST would be smart to partner with Kaly. But like everyone else in the market (besides us), they are unwilling to take on the risk and cash burden of a phase 3 trial. We need someone to pay for Kaly's cash burn, and $10s of millions in clinical trials. 

I doubled my position yesterday at 0.07. It is entirely possible I will lose my entire investment here. This is strictly a lotto play. I'm riskig $20,000 for the reward of $200,000. This is how NOT to invest, btw. But what can i say, im a gambler.